JUN 24, 2019 8:27 AM PDT

New Drug Target for Chemically-Induced Parkinson Disease

WRITTEN BY: Nouran Amin

Once upon a time, a compound found in synthetic opioid, MPTP induced the onset of Parkinson's disease. Early studies show that MPTP induces Parkinson disease in rodents and primates. The most recent study indicates that a naturally-occurring enzyme, known as mitochondrial CYP2D6, can metabolize certain compounds into MPTP-like chemicals and trigger Parkinson in mouse studies. Now, researchers are proposing a new treatment for chemically-induced Parkinson via targeting the mitochondrial CYP2D6 enzyme.

PennToday: Findings from Penn Vet suggest a potential new target for treating Parkinson’s, an enzyme that wreaks its damage on dopamine-producing neurons. Credit: PennToday.UPenn.edu

"Over the past two or three decades, researchers have tried inhibiting the process by which they believed MPTP was metabolized, with mixed success," says research leader, Narayan Avadhani. "We believe that mitochondrial CYP2D6 is the more direct drug target, which might prove better in treating idiopathic Parkinson's disease."

Learn more about Parkinson Disease:

Findings of the study were published in the Journal of Biological Chemistry and investigates the mechanism of Parkinson's disease with unknown causes. Current mechanism of action is believed to involve the oxidation of compounds to form MPP+--a toxic metabolite thought to be transferrable to dopamine neurons via dopamine transporter proteins. The process seemed logical since Parkinson disease is characterized by unusually low dopamine levels in the brain.

PennToday: The new model overturns a current paradigm of how chemical insults lead to Parkinson’s disease. (Image: Avadhani lab)

Targeting the mechanism of action, researchers showed that mice lacking CYP2D6 did not present with any severe symptoms that mice with the protein did. Furthermore, a CYP2D6 inhibitor was seen to prevent neuronal damage in mice.

"CYP2D6 is known to play a role in influencing the activity of a number of drugs," says Avadhani. "The CYP2D6 inhibitor ajmalicine is a member of the reserpine family of alkaloids, found in the plant Rauwolfia serpentine and was long used in India for treating mental illness, such as paranoia and schizophrenia. Mitochondrial targeting of such compounds is likely to be effective in treating Parkinson's patients, and pursuing that is our future strategy."

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUN 07, 2022
Cell & Molecular Biology
Advances in Laboratory Automation Research at the 2022 Labroots Virtual Event
JUN 07, 2022
Advances in Laboratory Automation Research at the 2022 Labroots Virtual Event
Labroots hosted its 6th Annual Laboratory Automation Virtual Event on May 18, 2022. The speaker roster for this free con ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
JUL 28, 2022
Cannabis Sciences
FDA Approved Cannabis Drug Products
JUL 28, 2022
FDA Approved Cannabis Drug Products
The FDA has approved some cannabis infused drugs for medical usage. Here's what they are.
AUG 08, 2022
Immunology
Controls and Calibrators for Measurement Assurance in Flow Cytometry: New Applications and New Requirements
AUG 08, 2022
Controls and Calibrators for Measurement Assurance in Flow Cytometry: New Applications and New Requirements
One of the primary objectives for the application of flow cytometry in any testing environment should be measurement ass ...
AUG 12, 2022
Cannabis Sciences
Study Shows Water Soluble CBD Has Better Absorption than Oil-Based CBD Products
AUG 12, 2022
Study Shows Water Soluble CBD Has Better Absorption than Oil-Based CBD Products
Colorado State University researchers examined the pharmacokinetics of cannabidiol (CBD) and its impact on liver functio ...
AUG 16, 2022
Drug Discovery & Development
Blood Pressure Drug Shows Promise for Treating ALS
AUG 16, 2022
Blood Pressure Drug Shows Promise for Treating ALS
Terazosin, a drug currently approved to treat high blood pressure and enlarged prostate, may also be able to treat ALS. ...
Loading Comments...